Bioprospecting of an Endolichenic Fungus Phanerochaete sordida Isolated from Mangrove-Associated Lichen Bactrospora myriadea
Author(s) -
Ramani H. Weerasinghe,
Chaitrali Shevkar,
Kasun Maduranga,
Komal Pandey,
R.N. Attanayake,
Abhijeet S. Kate,
Gothamie Weerakoon,
Santosh Kumar Behera,
Kiran Kalia,
P.A. Paranagama
Publication year - 2022
Publication title -
journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 50
eISSN - 2090-9063
pISSN - 2090-9071
DOI - 10.1155/2022/3193689
Subject(s) - chemistry , abts , ethyl acetate , fractionation , ic50 , nuclear chemistry , bioassay , stereochemistry , chromatography , antioxidant , dpph , in vitro , organic chemistry , biology , biochemistry , genetics
Bioassay-guided fractionation of the ethyl acetate extract of Phanerochaete sordida, an endolichenic fungus (ELF) isolated from the host lichen Bactrospora myriadea, collected from Negombo lagoon, Sri Lanka, led to the isolation of a bioactive compound. Following the identification of the fungus using morphological and DNA barcoding techniques, the pure compound was isolated using column chromatography, preparative TLC, and semipreparative HPLC. The structure elucidation was carried out using IR, HR-ESI-MS and 1H, 13C & 2D NMR spectroscopic methods. The in vitro bioassays conducted revealed that compound 1 has a high antioxidant activity with ABTS•+ (IC50 58.91 ± 1.35 μ M ), moderate anti-inflammatory activity (IC50 254.79 ± 1.41 μ M ), comparable antibacterial activity against the oral-bacterial strain Streptococcus mutans (MIC 898.79 μM and MLC 1797.58 μM), moderate tyrosinase inhibition (IC50 1713.69 ± 8.65 μ M ), and moderate cytotoxicity against oral cancer (IC50 13.65 ± 0.02 μ M ), in comparison with respective positive controls. The in silico experiments conducted for tyrosinase inhibition and cytotoxicity using Schrödinger revealed results in line with the in vitro results, thus confirming the bioactivities. The molecule also satisfies the key features of drug likeliness according to pharmacokinetic studies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom